ADC Therapeutics S.A.
NYSE:ADCTBiotechnology
-$0.02 today
- Market cap
- $192.71M
- Beta
- 1.77
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$0.89
Volume 1.17M
Average 1.68M
ADCT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
ADC Therapeutics S.A.NYSE: ADCT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $19.88M fell 31.3% year over year, behind the -15.8% change in trailing-twelve-month research & development. Sequentially, it rose 9.3% from the prior quarter. Over 3 fiscal years it compounded at -17.7% a year.
Context
- Research & development amounted to 127.8% of revenue in FY2025, down 26.9 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -31.3% toward the trailing-twelve-month pace of -15.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 104.01M USD
- Year-over-year change
- -5.1%
- 4-year CAGR
- -9.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 104.01M | -5.1% |
| FY2024 | 2024-12-31 | 109.63M | -13.8% |
| FY2023 | 2023-12-31 | 127.13M | -31.8% |
| FY2022 | 2022-12-31 | 186.46M | +18.0% |
| FY2021 | 2021-12-31 | 158M | — |
Research & Development vs competitors
How ADCT compares with its peers on the latest reported figures
- ADCT's LTM Mar 2026 research & development of $94.95M is the 6th highest of the 10 companies compared; the peer median is $112.11M.
- Its year-over-year change of -15.8% is the 6th highest of 10, against a peer median of -11.0%.
- Research & development amounts to 119.9% of revenue for ADCT, versus a peer median of 305.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $346.63M | -8.7% | +56.3% | 4685.4% |
| LTM Mar 2026 | $230.13M | +16.7% | +43.3% | 362.4% | |
| LTM Mar 2026 | $219.98M | +42.7% | +34.6% | 249.3% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $162.51M | -21.6% | +18.9% | — |
| LTM Mar 2026 | $112.11M | -27.3% | +3.1% | 121.1% | |
| LTM Mar 2026 | $94.95M | -15.8% | -17.7% | 119.9% | |
| LTM Mar 2026 | $70.57M | -39.3% | -10.3% | 713.3% | |
| LTM Mar 2026 | $58.28M | -31.8% | +5.0% | 83.7% | |
| LTM Mar 2026 | $54.53M | -11.0% | -9.3% | 2944.3% | |
| LTM Mar 2026 | $18.85M | +49.9% | +8.2% | 127.5% | |
| Peer median (excluding ADCT) | $112.11M | -11.0% | +8.2% | 305.9% | |
Competitors are the stored peer set for ADCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.92M | 209.91M | 69.56M | 70.84M | 81.36M |
| Cost of Revenue | 1.39M | 3.3M | 2.53M | 5.95M | 7.67M |
| Gross Profit | 32.52M | 206.61M | 67.03M | 64.89M | 73.68M |
| Gross Margin | 95.9% | 98.4% | 96.4% | 91.6% | 90.6% |
| Research & Development | 158M | 186.46M | 127.13M | 109.63M | 104.01M |
| Selling, General & Admin | 136.24M | 143.49M | 105.89M | 85.91M | (6.82M) |
| Operating Expenses | 294.24M | 329.95M | 233.02M | 195.54M | 182.06M |
| Depreciation & Amortization | 2.63M | 2.39M | 3.27M | 3.28M | 1.88M |
| EBITDA | (230.54M) | (107.7M) | (145.83M) | (102.65M) | (89.27M) |
| EBITDA Margin | -679.7% | -51.3% | -209.6% | -144.9% | -109.7% |
| Operating Income | (261.72M) | (123.34M) | (165.99M) | (130.65M) | (108.38M) |
| Operating Margin | -771.6% | -58.8% | -238.6% | -184.4% | -133.2% |
| Interest Income | 66K | 2.57M | 10.54M | 12.27M | 8.81M |
| Interest Expense | 18.34M | 36.73M | 46.33M | 50.21M | 51.63M |
| Other Income / Expenses | 10.22M | (33.56M) | (34.96M) | (27.03M) | (34.4M) |
| Income Before Tax | (251.51M) | (156.9M) | (200.95M) | (157.68M) | (142.78M) |
| Pre-Tax Margin | -741.5% | -74.7% | -288.9% | -222.6% | -175.5% |
| Income Tax Expense | (21.48M) | 227K | 39.11M | 166K | (157K) |
| Net Income | (230.03M) | (157.13M) | (240.05M) | (157.85M) | (142.62M) |
| Net Margin | -678.2% | -74.9% | -345.1% | -222.8% | -175.3% |
| EPS (Basic) | (3.00) | (1.99) | (2.94) | (1.62) | (1.12) |
| EPS (Diluted) | (3.00) | (1.99) | (2.94) | (1.62) | (1.12) |
| Weighted Avg Shares | 76.75M | 78.15M | 81.71M | 97.16M | 127.07M |
| Weighted Avg Shares (Diluted) | 76.75M | 78.15M | 81.71M | 97.16M | 127.07M |
ADC Therapeutics S.A.
NYSE:ADCT
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.